E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Systemic Lupus Erythematosus (SLE) |
Lupus eritematoso sistemico (LES) |
|
E.1.1.1 | Medical condition in easily understood language |
Systemic Lupus Erythematosus (SLE) |
Lupus eritematoso sistemico (LES) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025139 |
E.1.2 | Term | Lupus erythematosus systemic |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the safety and tolerability of LY2127399 (120 mg every 4 weeks [Q4W] + SoC or 120 mg every 2 weeks [Q2W] + SoC) in patients with SLE who have completed 52 weeks of treatment in either Study BCDS or Study BCDT. Safety and tolerability assessments for Study BCDX include the following: - Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) - Laboratory evaluations (including chemistry, immunoglobulins, hematology, B cell counts, and urinalysis) - Immunogenicity (anti-LY2127399 antibodies) |
L’obiettivo primario di questo studio e' valutare la sicurezza e la tollerabilita' di LY2127399 (120 mg ogni 4 settimane [Q4W] + SoC o 120 mg ogni 2 settimane [Q2W] + SoC) in pazienti con LES che hanno completato 52 settimane di trattamento in uno dei due studi BCDS o BCDT. Le valutazioni di sicurezza e tollerabilita' per lo studio BCDX comprendono i seguenti accertamenti: eventi avversi insorti durante il trattamento (TEAE), eventi avversi di particolare interesse (AESI) ed eventi avversi seri (SAE); parametri di laboratorio (inclusi i parametri ematochimici ed ematologici, i livelli di immunoglobuline, le conte delle cellule B e le analisi delle urine); immunogenicita' (anticorpi anti-LY2127399). |
|
E.2.2 | Secondary objectives of the trial |
The following secondary objectives of this study will examine the effect over time during long-term administration of LY2127399 on the following outcomes:- Proportion of patients who achieve a response over time as defined by the SLE responder index-5 (SRI-5). - Proportion of patients who achieve a response as defined by each subcomponent of SRI-5. - Proportion of patients who achieve a response as defined by the SRI-4, the SRI-6, and the SRI-7. - Proportion of patients able to decrease dose to 7.5 mg/day or less of prednisone or equivalent, with quiescent disease (BILAG C score or better in all 9 systems) and no flares (BILAG A or B) for at least 3 consecutive months. - Change in anti-double-stranded deoxyribonucleic acid (anti-dsDNA) level. - Change in SLE Disease Activity Index-2000 (SLEDAI-2K) score. - Proportion of patients with new severe SLE flares (modified SELE... |
I seguenti obiettivi secondari di questo studio valuteranno l’effetto della somministrazione a lungo termine di LY2127399 sui seguenti esiti: percentuale di pazienti che ottengono una risposta nel tempo,come risulta dall’indice di risposta SRI-5 (SLE responder index-5).La risposta SRI-5 e' definita come: o riduzione >=5 punti nel punteggio SELENA-SLEDAI rispetto al basale; o assenza di nuovi punteggi BILAG A o non piu' di 1 nuovo punteggio BILAG B relativo all’attivita' della malattia; e o assenza di peggioramento (definito come aumento >=0,3 punti rispetto al basale) alla scala PGA; percentuale di pazienti che ottengono una risposta,come definito da ciascun subcomponente dell’indice SRI-5 menzionato sopra; percentuale di pazienti che ottengono una risposta come definito dagli indici SRI-4,SRI-6 e SRI-7; percentuale di pazienti in grado di ridurre la dose a <=7,5 mg/die |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients are eligible to be included in the study only if they meet all of the following criteria: - Have completed 52 weeks of treatment in Study BCDS or Study BCDT. - For female patients of childbearing potential, must test negative for pregnancy at the time of enrollment and agree to use a reliable method of birth control or remain abstinent during the study or for at least 8 weeks following the last dose of study drug, whichever is longer, or - For female patients of non-childbearing potential, defined as: • Women who have had surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) • Women ≥60 years of age • Women ≥40 and <60 years of age who have had a cessation of menses for at least 12 months and a follicle-stimulating hormone (FSH) test confirming non-childbearing potential (FSH ≥40 mIU/mL). - Have given written informed consent approved by Lilly or its designee and the Investigational Review Board/Ethical Review Board (IRB/ERB) governing the site. |
Sono idonei all’inclusione nello studio i pazienti che soddisfano tutti i criteri seguenti. [1] Completamento delle 52 settimane di trattamento nello Studio BCDS o BCDT. [2a] Per le donne in eta' fertile: risultato negativo al test di gravidanza effettuato all’arruolamento e consenso a utilizzare un metodo contraccettivo affidabile o a praticare l’astinenza per la durata dello studio o per almeno 8 settimane dall’ultima dose di farmaco in studio, a seconda di quale periodo sia piu' lungo; oppure [2b] donne non in eta' fertile, definite come: • donne sottoposte a sterilizzazione chirurgica (isterectomia, ovariectomia bilaterale o legatura delle tube); • donne di eta' ≥60 anni; • donne di eta' compresa tra 40 e 60 anni in post-menopausa da almeno 12 mesi e che presentano valori di ormone follicolo stimolante (FSH) ≥40 mIU/mL a conferma dell’impossibilita' di sviluppare una gravidanza. [3] Firma del consenso informato scritto approvato da Lilly o da un suo incaricato e dal Comitato di revisione istituzionale/Comitato di revisione etica (IRB/ERB) competente per il centro. |
|
E.4 | Principal exclusion criteria |
Patients will be excluded from the study if they meet any of the following criteria: - Presence of significant uncontrolled cerebrocardiovascular (for example: myocardial infarction [MI], unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic or neuropsychiatric disorders, or abnormal laboratory values at baseline that in the opinion of the Investigator pose an unacceptable risk to the patient if study drug would be administered. - Have any other condition that renders the patient unable to understand the nature, scope, and possible consequences of the study or precludes the patient from following and completing the protocol, in the opinion of the Investigator. - Are unwilling or unable to comply with study procedures. - Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. - Are Lilly employees or representatives of a third party organization (TPO) involved in the study who require exclusion of their employees. |
Saranno esclusi dallo studio i pazienti che soddisfano uno qualsiasi dei criteri seguenti. [4] Significativi disturbi cerebro-cardiovascolari (p. es. infarto del miocardio [MI], angina instabile, ipertensione arteriosa instabile, grave insufficienza cardiaca o accidente cerebrovascolare), respiratori, epatici, renali, gastrointestinali, endocrini, ematologici o neuropsichiatrici non controllati o anomalie nei parametri di laboratorio al basale che nell’opinione dello Sperimentatore rappresenterebbero un rischio inaccettabile per il/la paziente qualora gli/le fosse somministrato il farmaco in studio. [5] Qualsiasi altra patologia che, nell’opinione dello Sperimentatore, impedisce al/la paziente di comprendere la natura, le finalita' e le possibili conseguenze dello studio o di rispettare e completare il protocollo. [6] Impossibilita' o rifiuto di aderire alle procedure dello studio. [7] Il/La paziente e' un membro del personale del centro di sperimentazione direttamente coinvolto in questo studio e/o un parente stretto di un membro del personale di studio. Per parente stretto si intendono coniugi, genitori, figli/e o fratelli/sorelle, sia per legame biologico che per adozione legale. [8] Il/La paziente e' un dipendente di Lilly o un rappresentante di un’organizzazione terza coinvolta nello studio che prevede l’esclusione dei propri dipendenti. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of Study BCDX is to evaluate the safety and tolerability of LY2127399 in patients with SLE who have completed 52 weeks of treatment in either Study BCDS or Study BCDT. Safety and tolerability assessments will include frequency of TEAEs and SAEs and laboratory evaluations. |
L’end point primario dello studio BCDX e' valutare la sicurezza e la tollerabilita' di LY2127399 in pazienti con LES che hanno completato 52 settimane di trattamento in uno dei due studi BCDS o BCDT. Le valutazioni di sicurezza e tollerabilita' per lo studio BCDX includeranno la frequenza dei TEAE dei SAE e degli esami di laboratorio. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
End of study. |
Conclusione dello studio. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Not applicable |
Non applicabile |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Dosing intervals of 120 mg every 2 weeks versus every 4 weeks |
Intervalli di dosaggio da 120 mg ogni 4 settimane in confronto a 120 mg ogni 2 settimane |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
2 bracci di studio per investigare gli intervalli di dosaggio ( 2 settimane verso 4 settimane) |
2 arm study to investigate dosing intervals (2 weeks versus 4 weeks) |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 100 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Belarus |
Brazil |
Canada |
Chile |
Colombia |
Croatia |
Ecuador |
Egypt |
Guatemala |
India |
Israel |
Japan |
Korea, Republic of |
Macedonia, the former Yugoslav Republic of |
Malaysia |
Mexico |
New Zealand |
Peru |
Philippines |
Russian Federation |
Singapore |
South Africa |
Taiwan |
Thailand |
Tunisia |
Turkey |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study (trial) is the date of the last visit or last scheduled procedure shown in the Study Schedule for the last active patient in the study. |
La conclusione dello studio (sperimentazione) e' la data dell'ultima visita o dell'ultima procedura programmata dimostrata nel programma di studio dell'ultimo paziente attivo nello studio. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 67 |
E.8.9.1 | In the Member State concerned days | 14 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |